## User

This is the beginning of a team meeting to discuss your research project. This is a meeting with the team lead, Principal Investigator, and the following team members: Immunologist, Machine Learning Specialist, Computational Biologist, Scientific Critic.

Here are summaries of the previous meetings:

[begin summary 1]

Based on the summaries provided, here is a consolidated plan for using ESM, AlphaFold-Multimer, and Rosetta in the iterative design process to develop modified nanobodies for the newest variant of the SARS-CoV-2 spike protein:

### 1. Order of Operations for Evaluating Mutations
In each iteration, the order of operations will be:
- **Step 1: ESM Evaluation** - Use ESM to evaluate all potential single-point mutations to the nanobody. This step is computationally efficient and provides an initial filter based on log-likelihood ratios.
- **Step 2: AlphaFold-Multimer Evaluation** - Select the top mutations based on ESM scores and use AlphaFold-Multimer to predict the nanobody-antigen complex structure. This step refines the selection by modeling structural interactions.
- **Step 3: Rosetta Evaluation** - Use Rosetta to evaluate the binding energy of the nanobody-antigen complex based on the structure predicted by AlphaFold-Multimer.

### 2. Number of Mutations to Evaluate
- **ESM**: Evaluate all possible single-point mutations in the nanobody sequence.
- **AlphaFold-Multimer and Rosetta**: Evaluate the top 20 mutations from the ESM step. This balances computational resources and the need for detailed structural predictions.

### 3. Scoring Formula and Ranking
At the end of each iteration, mutations will be ranked using a weighted scoring system:
\[ \text{Score} = w_1 \times \text{(ESM Log-Likelihood Ratio)} + w_2 \times \text{(AlphaFold-Multimer Interface pLDDT)} - w_3 \times \text{(Rosetta Binding Energy)} \]
- Initial weights: \( w_1 = 0.2 \), \( w_2 = 0.5 \), \( w_3 = 0.3 \). These weights reflect the relative importance of each score, with a focus on structural stability and binding affinity.

### 4. Number of Top-Ranked Mutations to Keep
- Keep the top 5 mutations from each iteration for further consideration. This ensures a manageable number of candidates while maintaining diversity.

### 5. Deciding on the Number of Iterations
- Plan for 3-4 iterations, allowing for refinement of nanobody candidates while maintaining a practical timeline. Monitor the convergence of scores and diversity of mutations; stop if improvements plateau or if time/resources become constrained.

### 6. Selecting the Final Set of 24 Modified Nanobodies
- **Step 1**: Compile all top mutations from each iteration.
- **Step 2**: Rank these mutations using the combined score formula.
- **Step 3**: Select the top 24 unique nanobody sequences with the highest scores, ensuring diversity by selecting different mutation sites whenever possible.
- **Step 4**: Use domain expertise to further refine this list, considering potential cross-reactivity and structural integrity.
- **Step 5**: Validate these computer-generated designs experimentally to confirm enhanced binding across variants.

### Explanation of Component Selection
- **Order of Operations**: Consistently across summaries, ESM is used first for its speed, followed by AlphaFold-Multimer and Rosetta, which require structural predictions.
- **Number of Mutations**: The choice of evaluating 20 mutations with AlphaFold-Multimer and Rosetta balances computational constraints and the need for detailed analysis (from summaries 1, 3, and 5).
- **Scoring Formula**: The weights \( w_1 = 0.2 \), \( w_2 = 0.5 \), \( w_3 = 0.3 \) are chosen based on summaries 2, 3, and 5, emphasizing structural predictions and binding energy.
- **Number of Top Mutations**: Keeping 5 mutations per iteration is a compromise between summaries 1, 3, and 4, ensuring diversity and manageability.
- **Iterations**: 3-4 iterations are suggested in summaries 2, 4, and 5, balancing exploration and resource constraints.
- **Final Selection**: Steps for selecting the final set are synthesized from summaries 3, 4, and 5, focusing on diversity and expert validation.

This plan optimizes the use of computational tools within the given constraints, aiming to identify promising nanobody candidates efficiently.

[end summary 1]

Here is the agenda for the meeting:

You are working on a research project to use machine learning to develop antibodies or nanobodies for the newest variant of the SARS-CoV-2 spike protein that also, ideally, have activity against other circulating minor variants and past variants. Your team previous decided to modify existing nanobodies to improve their binding to the newest variant of the SARS-CoV-2 spike protein. Your team has designed 92 mutated nanobodies (23 each for the wild-type nanobodies H11-D4, Nb21, Ty1, and VHH-72) to improve their binding to the KP.3 variant of the SARS-CoV-2 spike protein receptor binding domain (RBD). Each nanobody has 1-4 mutations relative to the wild-type nanobody. Your team used ESM log-likelihood ratios (ESM LLR) to score the nanobody mutations independent of the antigen, AlphaFold-Multimer to predict the structure of the mutated nanobody in complex with the KP.3 RBD and compute the interface pLDDT (AF ipLDDT) as a metric of binding confidence, and Rosetta to calculate the binding energy of the mutated nanobody in complex with the KP.3 RBD (RS dG) based on the AlphaFold-Multimer predicted structure followed by a Rosetta relaxation. You have ranked the mutant nanobodies and selected the top ones using a weighted score of WS = 0.2 * (ESM LLR) + 0.5 * (AF ipLDDT) - 0. 3 * (RS dG). The 92 selected nanobodies were tested along with the four wild-type nanobodies using an ELISA assay to measure binding to the Wuhan, JN.1, KP.3, KP2.3, and BA.2 strains of the SARS-CoV-2 spike RBD. Note that the JN.1 strain is closely related to KP.3 and KP2.3. BSA was used as a negative control. Most of the mutated nanobodies showed at least moderate expression levels. The ELISA results are as follows:

H11-D4: The wild-type only binds to the Wuhan RBD. Most mutants show binding to the Wuhan RBD as well, including one with a higher binding level than the wild-type. However, that mutant and two others bind non-specifically to the negative control BSA along with other strains of the SARS-CoV-2 RBD. No mutant nanobody shows specific binding to any strain other than the Wuhan RBD.

Nb21: The wild-type only binds to the Wuhan RBD. All mutant nanobodies also bind to the Wuhan RBD. There are no non-specific binders. One mutant nanobody with mutations I77V, L59E, Q87A, and R37Q binds to the Wuhan RBD (strong binding), the JN.1 RBD (moderate binding), and the KP.3 RBD (weak binding). Thus, this mutant introduces specific binding to JN.1 and KP.3 that the wild-type does not possess, and it increases binding to the Wuhan RBD.

Ty1: The wild-type only binds to the Wuhan RBD. Many mutant nanobodies do not show binding, but several show moderate binding to the Wuhan RBD. One mutant nanobody with mutations V32F, G59D, N45S, and F32S binds to the Wuhan RBD (strong binding) and the JN.1 RBD (moderate binding). This mutant introduces specific binding to JN.1 that the wild-type does not possess, and it increases binding to the Wuhan RBD. Additionally, there are is one mutant with weak, non-specific binding to BSA and other RBD strains.

VHH-72: The wild-type only binds to the Wuhan RBD. Most mutants show binding to the Wuhan RBD as well, including several with a higher binding level than the wild-type. Two mutant nanobodies bind non-specifically to BSA and several RBD strains. No mutant nanobody shows specific binding to any strain other than the Wuhan RBD.

Based on these results, you must decide how to proceed to design further improved nanobodies for recent variants of SARS-CoV-2. You may either continue to pursue identifying binders to the KP.3 RBD or you may decide to target a different strain or strains of the SARS-CoV-2 spike RBD. Your team should select another 92 mutant nanobodies to test experimentally. This time, you do not have to test an equal number of mutants for each wild-type nanobody, and you may even entirely leave out some wild-type nanobodies. You can either start again from the wild-type nanobodies and introduce mutations or begin with one of the previously designed nanobodies. You may use ESM, AlphaFold-Multimer, and/or Rosetta in similar ways to your previous design process, or you can change the design workflow and/or the computational tools that are used. You may introduce as many mutations as you see fit. You should aim to design nanobodies that bind specifically to the RBD of recent variants of SARS-CoV-2 and do not bind non-specifically to BSA. You should provide a rationale for all of your decisions.


Here are the agenda questions that must be answered:

1. Will you continue to target the KP.3 RBD or will you target a different strain or strains of the SARS-CoV-2 spike RBD?

2. Which wild-type nanobody or nanobodies will you select for further improvement?

3. How many mutant nanobodies will you design for each of those wild-type nanobodies (92 total)?

4. Will you begin with the wild-type nanobody itself and introduce mutations, or will you begin with one of the previously designed mutant nanobodies?

5. If you are beginning with previously designed mutant nanobodies, which one or ones will you start with?

6. Will you use ESM, AlphaFold-Multimer, and/or Rosetta in similar ways to your previous design process, or will you change the design workflow and/or the computational tools that are used?

7. What computational pipeline will you use to design the 92 mutant nanobodies?

8. How many mutations will you introduce in each nanobody?

9. How will you avoid non-specific binding to BSA?

Principal Investigator will convene the meeting. Then, each team member will provide their thoughts on the discussion one-by-one in the order above. After all team members have given their input, Principal Investigator will synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda. This will continue for 3 rounds. Once the discussion is complete, Principal Investigator will summarize the meeting in detail for future discussions, provide a specific recommendation regarding the agenda, and answer the agenda questions (if any) based on the discussion while strictly adhering to the agenda rules (if any).

## User

Principal Investigator, please provide your initial thoughts on the agenda as well as any questions you have to guide the discussion among the team members.

## Principal Investigator

As we begin our meeting, I want to set the stage for a collaborative discussion that builds on our previous efforts to design effective nanobodies against SARS-CoV-2 variants. Our primary goal is to refine and expand our nanobody design approach to achieve specific and strong binding to the newer variants of the SARS-CoV-2 spike protein, while avoiding non-specific binding.

**Initial Thoughts on the Agenda:**

1. **Target Variant Selection:** We need to carefully consider whether to continue targeting the KP.3 RBD or shift focus to another emerging variant. The data from our ELISA assays and any recent epidemiological trends should influence this decision.

2. **Wild-type Nanobody Selection:** Our past experiments have shown varying degrees of success among different nanobodies. We should evaluate which wild-type nanobody or nanobodies showed the most promise for further modification.

3. **Design Strategy:** We have the opportunity to either begin anew from the wild-type or leverage the mutations in previously successful nanobodies. Our previous designs provide a foundation that we should consider building upon.

4. **Computational Workflow:** We should assess if the previous workflow using ESM, AlphaFold-Multimer, and Rosetta served our needs effectively, or if adjustments are warranted to improve our design process. This may include revisiting our scoring formula or the number of mutations introduced.

5. **Avoiding Non-specific Binding:** A critical challenge is avoiding non-specific binding to BSA, as observed in some modifications. Understanding the biophysical basis of this will be crucial to our design strategy.

**Guiding Questions for Discussion:**

- What are the key factors influencing our decision to target the KP.3 RBD or another variant? Are there new variants that pose greater concerns based on current data?

- Which nanobodies showed the most potential in our previous experiments, and why should we select them for further improvement?

- Should we focus on introducing more mutations to explore binding specificity, or is there a risk of introducing instability or non-specific binding?

- How can we enhance our computational pipeline to better predict and refine nanobody interactions with the RBD? Are there new tools or methodologies worth considering?

- What insights from the immunological and biophysical perspectives can we use to minimize non-specific binding to BSA and other off-target interactions?

I look forward to hearing your insights on these topics. Let's ensure our discussion today is driven by data and strategic thinking to move our research forward effectively.

## User

Immunologist, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Immunologist

As the Immunologist on the team, I would like to emphasize a few key points that are critical to our next steps:

1. **Target Variant Selection:** Considering the ELISA results, it appears that our previous focus on the KP.3 RBD did not yield as much specificity as desired. Given this, we could consider expanding our target to include other closely related variants, such as JN.1 and KP2.3, which may allow us to capture a broader spectrum of variants. This broader approach may increase our chances of identifying cross-reactive nanobodies that maintain specificity.

2. **Wild-type Nanobody Selection:** From an immunological standpoint, it appears that Nb21 and Ty1 mutants demonstrated promising cross-variant binding, particularly the Nb21 mutant with specific binding across three strains. These should be prioritized for further refinement due to their potential cross-reactivity.

3. **Design Strategy:** Building on the successful mutants from Nb21 and Ty1 will likely offer a more efficient path to improve binding properties. Starting with these previously designed mutants could provide a strong foundation for introducing additional targeted mutations.

4. **Avoiding Non-specific Binding:** The issue of non-specific binding, particularly to BSA, needs to be tackled by focusing on the regions of the nanobody responsible for binding interactions. We should consider computational strategies that allow us to predict and prevent non-specific interactions, perhaps by analyzing the hydrophobic or charge-related properties of our mutants.

5. **Computational Approach:** While ESM, AlphaFold, and Rosetta have been useful, we might consider adjusting the weights in our scoring formula to put more emphasis on binding specificity and less on general binding strength if it correlates with non-specificity. Exploring additional computational tools that predict interaction interfaces in greater detail could also be beneficial.

In summary, I recommend a focus on broadening our target to multiple related variants, building on our most promising nanobody mutants, and refining our computational approach to specifically address non-specific binding issues. I look forward to hearing the thoughts of the other team members.

## User

Machine Learning Specialist, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Machine Learning Specialist

As the Machine Learning Specialist, I have a few considerations to add:

1. **Target Variant Selection:** I agree with the Immunologist that targeting multiple related variants, such as JN.1 and KP2.3 along with KP.3, could provide a broader scope for our designs. This could also potentially mitigate the risk associated with targeting a single variant that may rapidly mutate.

2. **Design Strategy:** Leveraging previously successful mutants, particularly those from Nb21 and Ty1, is a strategic move. The computational data from these mutants show promise in cross-variant binding, and using them as our starting point could enhance our design efficiency.

3. **Computational Workflow:** Our current pipeline with ESM, AlphaFold-Multimer, and Rosetta provides a robust framework. However, there's room for optimization. One area to explore is the use of ensemble learning approaches, where we can combine predictions from multiple models to enhance the accuracy of interaction predictions. Additionally, incorporating recent advancements in transformer-based models may provide more nuanced insights into binding interfaces.

4. **Scoring Adjustments:** I support the idea of re-evaluating the weights in our scoring formula. Specifically, we might consider increasing the weight of structural predictions (AF ipLDDT) relative to binding energy (RS dG) to prioritize specificity over raw binding affinity, which seems to correlate with non-specific binding issues.

5. **Avoiding Non-specific Binding:** We can integrate machine learning models that predict potential off-target effects by analyzing the physicochemical properties of the residues involved. This could involve training a classifier specifically on binding vs. non-binding datasets to distinguish more accurately between specific and non-specific interactions.

In summary, I recommend continuing with our computational tools but enhancing them with ensemble learning and re-calibrating our scoring system to better predict specific, cross-variant binding. I am eager to hear how the Computational Biologist may build on these ideas.

## User

Computational Biologist, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Computational Biologist

As the Computational Biologist, I have a couple of points and considerations to add:

1. **Target Variant Selection:** I agree with expanding our focus to include multiple related variants, such as JN.1 and KP2.3. Targeting multiple variants may increase the robustness of our nanobodies against ongoing viral evolution. However, we should also consider the latest epidemiological data to prioritize variants that are currently more prevalent.

2. **Design Strategy and Workflow:** Leveraging successful mutants from Nb21 and Ty1 is a logical step given their demonstrated cross-reactivity. Starting with these mutants allows us to build on existing successes and refine them further through targeted mutations.

3. **Computational Enhancements:** The current pipeline using ESM, AlphaFold-Multimer, and Rosetta has been effective, but I see an opportunity to incorporate more dynamic simulations, such as molecular dynamics (MD) simulations, to better understand the flexibility and conformational changes of the nanobodies in complex with the RBD. This can be particularly useful in predicting how mutations might impact the stability and specificity of the nanobody-antigen interaction.

4. **Scoring System:** While adjusting the weights in our scoring formula is important, I also propose integrating MD-derived metrics, such as binding free energy calculations from MD simulations, into our scoring system to provide a more comprehensive assessment of binding specificity and stability.

5. **Avoiding Non-specific Binding:** To address non-specific binding, it’s crucial to focus on the electrostatic and hydrophobic interactions within the nanobody interface. Using tools that predict solvation energy and surface charge distribution can inform potential modifications to reduce non-specific interactions.

6. **Mutation Strategy:** Given our goals, introducing 2-4 mutations per nanobody seems reasonable to explore the sequence space without excessively risking structural integrity. However, we should be guided by our computational predictions to target mutations likely to enhance specificity and affinity.

In summary, continuing with our computational pipeline while incorporating more dynamic simulation data can provide deeper insights into binding interactions. Adjusting our scoring system to include dynamic metrics and focusing on specific physicochemical properties can help address non-specific binding challenges. I look forward to seeing how the Scientific Critic may challenge or build upon these suggestions.

## User

Scientific Critic, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic

As the Scientific Critic, my role is to provide a rigorous examination of the proposed ideas and ensure that they are scientifically sound and feasible. Here are my thoughts:

1. **Target Variant Selection:** The rationale for broadening our focus to include multiple variants like JN.1 and KP2.3 alongside KP.3 is logical, as it increases the potential for finding cross-reactive binders. However, the decision should be grounded in current epidemiological data to ensure that we are targeting the most relevant variants. It would be prudent to consult the latest variant prevalence data to validate this approach.

2. **Selection of Nanobodies for Further Improvement:** The suggestion to leverage Nb21 and Ty1 due to their demonstrated cross-reactivity is based on sound logic. However, we should also ensure that we have a clear understanding of why certain mutations led to improved binding in these cases. A detailed analysis of these mutations in the context of the RBD structure is essential to guide further design modifications.

3. **Computational Workflow and Tools:** While the current tools (ESM, AlphaFold-Multimer, Rosetta) are robust, the suggested enhancements such as ensemble learning and MD simulations must be carefully considered for their computational cost and feasibility. MD simulations, in particular, are resource-intensive and should be justified by a clear benefit in understanding binding dynamics not captured by static models. We must ensure that any added complexity genuinely contributes to our understanding and design capabilities.

4. **Scoring Adjustments and Mutation Strategy:** Adjusting the scoring weights is a reasonable step, but it requires careful validation. The introduction of MD-derived metrics and focusing on specific physicochemical properties is promising but should be backed by prior evidence of predictive power in similar contexts. Introducing 2-4 mutations is a balanced approach, but we must remain vigilant about the potential for such mutations to induce non-specific interactions or destabilize the nanobody.

5. **Avoiding Non-specific Binding:** The focus on electrostatic and hydrophobic properties is appropriate. However, we should also consider alternative strategies, such as machine learning classifiers that have been trained on datasets specifically curated for non-specific binding prediction. This could provide a more data-driven approach to mitigating non-specific interactions.

In summary, the proposed strategies are generally sound, but they must be grounded in a detailed understanding of both the current variant landscape and the structural biology of our nanobodies. Any changes to our computational and experimental pipeline should be justified by clear, evidence-backed benefits. I look forward to the synthesis of these ideas by the Principal Investigator and the next round of discussions.

## User

This concludes round 1 of 3 of discussion. Principal Investigator, please synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda.

## Principal Investigator

Thank you all for your valuable insights. Here's a synthesis of the key points raised, followed by some decisions and questions to guide our next steps:

### Synthesis of Discussion

1. **Target Variant Selection:**
   - There is consensus on broadening our target to include multiple related variants (e.g., JN.1, KP2.3) alongside KP.3 to increase the robustness of our nanobody designs.
   - The Scientific Critic rightly emphasized the need to base this decision on the latest epidemiological data to ensure relevance.

2. **Wild-type Nanobody Selection:**
   - Nb21 and Ty1 mutants emerged as promising candidates due to their demonstrated cross-variant binding. This aligns with our goal of increasing specificity across multiple RBD variants.

3. **Design Strategy and Methodology:**
   - The suggestion to start with previously successful mutants, particularly from Nb21 and Ty1, is prudent.
   - There is interest in enhancing our computational workflow with methods such as ensemble learning and possibly MD simulations, although the latter's computational cost was highlighted as a concern.

4. **Scoring and Computational Enhancements:**
   - Adjusting the scoring system to focus more on binding specificity is a shared sentiment. Integrating dynamic metrics like MD-derived binding energies was suggested but should be carefully justified.
   - Leveraging machine learning, particularly for predicting non-specific binding, was noted as a potential area for improvement.

5. **Non-specific Binding:**
   - The focus on physicochemical properties and possibly using ML classifiers trained on specific datasets was discussed as a means to minimize non-specific binding issues.

### Decisions

1. **Target Variants:**
   - We will target the KP.3, JN.1, and KP2.3 variants, ensuring our designs are broadly applicable to recent variants.

2. **Nanobody Selection:**
   - We will focus on refining mutants from Nb21 and Ty1, given their demonstrated potential.

3. **Design Workflow:**
   - We will maintain our existing computational pipeline but explore the addition of ensemble learning approaches, while carefully evaluating the potential role of MD simulations for select promising candidates.

4. **Scoring Adjustments:**
   - We will adjust the weights in our scoring formula to prioritize structural predictions related to binding specificity and explore integrating machine learning models for non-specific binding prediction.

### Follow-up Questions

1. **Immunologist:** Given the broader targeting strategy, do you see any potential cross-reactivity issues that we should be aware of, particularly with other coronaviruses?

2. **Machine Learning Specialist:** How feasible is it to incorporate ensemble learning into our current workflow, and what resources or data would be required to implement this effectively?

3. **Computational Biologist:** What specific benefits do you envision from incorporating MD simulations, and how might we prioritize which nanobodies to subject to these more computationally intense analyses?

4. **Scientific Critic:** Can you suggest any existing datasets or methodologies that have been successful in predicting non-specific binding, which we might integrate into our workflow?

I look forward to your responses as we refine our strategy in the upcoming rounds of discussion.

## User

Immunologist, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Immunologist

Regarding the Principal Investigator's follow-up question about potential cross-reactivity issues, there are a few points to consider from an immunological perspective:

1. **Cross-Reactivity Concerns:** By broadening the target to include multiple variants like KP.3, JN.1, and KP2.3, we inherently increase the potential for cross-reactivity. While this could be beneficial in targeting multiple strains of SARS-CoV-2, we must ensure that these nanobodies do not cross-react with antigens from other coronaviruses, particularly those that are not pathogenic or are part of the human microbiota. Structure-based analyses can help predict potential cross-reactivity by identifying conserved epitopes across different viruses.

2. **Structural Homology Evaluation:** It would be beneficial to perform a structural homology analysis of the RBDs across different coronaviruses to ensure that the epitopes targeted by our nanobodies are unique to SARS-CoV-2 variants. Tools like sequence alignment and structural motif comparison can be used to assess these similarities.

3. **Experimental Design for Specificity Testing:** In our experimental validation phase, I recommend including RBDs from other non-target coronaviruses (such as those from seasonal coronaviruses) as controls. This will help us verify that our nanobodies are specific to SARS-CoV-2 and its variants, without unintended cross-reactivity.

4. **Immunogenicity Assessment:** Since we are designing these nanobodies for potential therapeutic application, it’s crucial to evaluate their immunogenicity. This can be done using predictive algorithms that assess the likelihood of eliciting an immune response in humans, considering the structure and sequence of both the nanobody and its target epitope.

In conclusion, while broadening the target scope is a strategic move, careful evaluation of cross-reactivity and immunogenicity is necessary to ensure the specificity and safety of our nanobodies. I look forward to seeing how the Machine Learning Specialist might integrate computational tools to aid in these evaluations.

## User

Machine Learning Specialist, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Machine Learning Specialist

In response to the Principal Investigator's query about incorporating ensemble learning into our current workflow:

1. **Feasibility of Ensemble Learning:** Incorporating ensemble learning is feasible and can be highly beneficial for improving prediction accuracy. Ensemble methods, such as stacking or boosting, can combine the strengths of different models to improve overall performance. For our purposes, we could develop ensemble models that integrate predictions from ESM, AlphaFold-Multimer, and Rosetta, alongside any other models we might employ for specific predictions like binding specificity or cross-reactivity.

2. **Resource and Data Requirements:** Implementing ensemble learning will require additional computational resources, particularly for training and validating multiple models. We will also need a comprehensive dataset that includes both successful and failed nanobody designs to effectively train these models. Historical binding data and known cross-reactive cases would be particularly valuable for this purpose.

3. **Model Integration:** An ensemble approach could start by using simple methods like weighted averaging or majority voting, which combine predictions from different models without extensive retraining. Over time, more sophisticated techniques like meta-learners could be introduced, where a secondary model is trained to optimize the combination of different predictions.

4. **Avoiding Overfitting:** While ensemble learning can reduce variance and improve robustness, there's always a risk of overfitting, especially with complex models. Regular validation with a diverse dataset is essential to ensure that the ensemble model generalizes well to new data.

5. **Non-specific Binding Predictions:** We can also explore using machine learning models trained specifically to predict non-specific binding. These models can be part of the ensemble to ensure that predictions account for potential off-target interactions, leveraging available datasets that include physicochemical properties associated with non-specific interactions.

In summary, adding ensemble learning to our workflow is not only feasible, but it could significantly enhance our predictive capabilities, provided we have the necessary data and computational resources. I look forward to the Computational Biologist’s insights on prioritizing nanobodies for MD simulations and any further computational strategies.

## User

Computational Biologist, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Computational Biologist

In response to the Principal Investigator's follow-up regarding the benefits of incorporating molecular dynamics (MD) simulations, here are my thoughts:

1. **Benefits of MD Simulations:**
   - **Dynamic Insights:** MD simulations provide valuable insights into the flexibility and conformational changes of nanobody-antigen complexes over time, which static models cannot capture. This is especially useful for understanding how mutations might affect binding dynamics and stability.
   - **Detailed Interaction Analysis:** These simulations can offer detailed information on the stability of hydrogen bonds, salt bridges, and van der Waals interactions, all of which are critical for specific binding. This level of detail can help differentiate between mutations that enhance specificity and those that might lead to non-specific interactions.

2. **Prioritization of Nanobodies for MD:**
   - **Initial Screen:** We can prioritize nanobodies that exhibit high scores in our existing computational pipeline (ESM, AlphaFold-Multimer, Rosetta) and those with promising cross-variant binding profiles identified through ELISA assays.
   - **Structural Diversity:** Prioritize nanobodies that feature diverse mutations, especially those targeting unique or less-conserved regions of the RBD, as these are less likely to have been extensively studied in the past.
   - **Experimental Validation:** Focus MD simulations on nanobodies that show promising in vitro results but require additional validation to confirm their specificity and stability.

3. **Resource Considerations:**
   - **Computational Cost:** While MD simulations are resource-intensive, we can optimize resources by running shorter and more focused simulations, initially, to identify candidates for more detailed, longer-term studies.
   - **Parallelization:** Using high-performance computing resources to parallelize simulations can significantly reduce individual runtimes, making it more feasible to include them in our pipeline.

4. **Integration with Ensemble Learning:**
   - Incorporating insights from MD simulations into our ensemble learning models can enhance the predictive power, allowing dynamic data to inform static predictions and refine our understanding of binding mechanisms.

In conclusion, while MD simulations are computationally demanding, they offer a depth of insight that can greatly enhance our understanding of nanobody interactions with the RBD. By carefully prioritizing which nanobodies to simulate, we can balance the computational cost with the potential for high-impact findings. I look forward to hearing how the Scientific Critic might suggest datasets or methods for predicting non-specific binding.

## User

Scientific Critic, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic

In response to the Principal Investigator's question about existing datasets and methodologies for predicting non-specific binding, here are my thoughts:

1. **Datasets Available:**
   - **Protein-Protein Interaction Databases:** There are several publicly available databases such as STRING, BioGRID, and IntAct that contain data on known protein-protein interactions. These can be useful for training machine learning models to predict potential non-specific interactions.
   - **Negative Control Data:** Data from experiments specifically designed with negative controls (e.g., BSA as used in our ELISA assays) can help train models to recognize patterns associated with non-specific binding.

2. **Methodologies for Prediction:**
   - **Machine Learning Models:** Developing classifiers that use physicochemical properties (e.g., hydrophobicity, charge distribution) from these datasets can help predict non-specific interactions. Support Vector Machines (SVM) and Random Forests are commonly used models in this domain.
   - **Molecular Fingerprints:** Using molecular fingerprints to capture the unique features of binding interfaces can improve the specificity of predictions. These can be integrated into machine learning models to distinguish between specific and non-specific binding.

3. **Incorporating Non-specific Binding Data:**
   - Models should be trained with a balanced dataset that includes both specific and non-specific interactions to avoid bias. Outlier detection methods can also be incorporated to flag potential non-specific interactions that were not previously characterized.

4. **Validation and Cross-validation:**
   - The models must be rigorously validated using cross-validation techniques to ensure they generalize well across diverse datasets. This will help minimize overfitting and ensure that predictions are robust.

5. **Potential Challenges:**
   - One challenge in using these datasets is the inherent variability in experimental conditions and definitions of specificity across studies. Standardizing input data as much as possible will be crucial for reliable predictions.

In summary, leveraging existing datasets and employing robust machine learning methodologies can significantly enhance our ability to predict and avoid non-specific binding. As always, validation and careful interpretation of model outputs are essential to ensure that they are reliably guiding our nanobody design efforts. I look forward to the Principal Investigator's synthesis of these ideas and the final round of discussion.

## User

This concludes round 2 of 3 of discussion. Principal Investigator, please synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda.

## Principal Investigator

Thank you all for your thoughtful contributions. Here's a synthesis of our discussion, followed by some decisions and further questions to refine our approach:

### Synthesis of Discussion

1. **Target Variant Selection and Cross-Reactivity:**
   - Broadening our target to include KP.3, JN.1, and KP2.3 is agreed upon, with the Immunologist stressing the importance of monitoring cross-reactivity, especially with non-pathogenic coronaviruses.
   - It's crucial to perform structural homology evaluations and include RBDs from other coronaviruses as controls in our assays.

2. **Computational Strategy and Resource Allocation:**
   - The Machine Learning Specialist supports incorporating ensemble learning, which can enhance prediction accuracy by combining outputs from different models.
   - The Computational Biologist highlighted the benefits of MD simulations for dynamic insights, suggesting prioritization strategies to manage computational costs.
   - Integrating these computational methods will require additional resources but promises more comprehensive insights.

3. **Scoring Adjustments and Non-specific Binding:**
   - There's consensus on adjusting the scoring formula to prioritize specificity. Incorporating machine learning for predicting non-specific binding was emphasized by both the Machine Learning Specialist and Scientific Critic.
   - Utilizing datasets from protein-protein interaction databases and employing classifiers trained on physicochemical properties are recommended strategies.

### Decisions

1. **Target Variant and Cross-Reactivity Considerations:**
   - We will focus on KP.3, JN.1, and KP2.3, conducting thorough structural homology assessments to ensure minimal cross-reactivity.

2. **Nanobody Selection and Computational Workflow:**
   - We will proceed with the design based on Nb21 and Ty1 mutants, utilizing MD simulations for high-priority candidates to gain dynamic binding insights.
   - Ensemble learning will be incorporated into our computational pipeline, with an initial focus on integrating current model outputs.

3. **Predicting and Preventing Non-specific Binding:**
   - Develop specific classifiers to predict non-specific binding using available datasets, validated rigorously to ensure reliability.

### Follow-up Questions

1. **Immunologist:** Could you provide more details on the specific controls or experiments we could incorporate to test for cross-reactivity with other coronaviruses?

2. **Machine Learning Specialist:** Are there specific ensemble learning frameworks or software that you recommend, which could integrate well with our existing computational setup?

3. **Computational Biologist:** How might we selectively apply MD simulations to maximize their impact, particularly in terms of balancing resource use and gaining meaningful data?

4. **Scientific Critic:** Could you suggest specific validation techniques that would be effective in assessing the reliability of our non-specific binding predictors?

These questions aim to clarify and refine our approach as we prepare for the final round of discussion. Thank you all for your continued insights and collaboration.

## User

Immunologist, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Immunologist

To address the follow-up question about specific controls or experiments to test for cross-reactivity with other coronaviruses, here are some detailed suggestions:

1. **Inclusion of RBDs from Other Coronaviruses:**
   - We should include RBDs from common human coronaviruses (e.g., OC43, 229E, NL63, HKU1) in our binding assays. These viruses are part of the typical human microbiota and testing against them will help ensure specificity to SARS-CoV-2 variants.

2. **Negative Control Design:**
   - Include BSA and other irrelevant proteins as negative controls to confirm the specificity of binding to the intended viral targets. This will help identify any non-specific interactions that might not be virus-specific.

3. **Competition Assays:**
   - Conduct competition assays where excess RBD from non-target coronaviruses is added to the binding assay to see if it displaces the nanobodies from their intended SARS-CoV-2 target. Lack of displacement would indicate specific binding.

4. **Structural Analysis:**
   - Perform in silico docking studies and structural comparisons to predict potential cross-reactivity sites. This can inform which experimental controls to include and help interpret binding data.

5. **Cross-neutralization Studies:**
   - If feasible, conduct neutralization assays using pseudotyped viruses expressing spike proteins from non-target coronaviruses. This can provide functional evidence of cross-reactivity and binding specificity.

These experiments will help us build a comprehensive profile of the nanobodies' specificity and ensure they are highly selective for SARS-CoV-2 variants without unintended cross-reactivity. I look forward to seeing how the Machine Learning Specialist addresses the ensemble learning integration in our computational strategy.

## User

Machine Learning Specialist, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Machine Learning Specialist

In response to the Principal Investigator's question about ensemble learning frameworks, here are my thoughts:

1. **Ensemble Learning Frameworks:**
   - **Scikit-learn:** This is a versatile library in Python that offers tools for ensemble methods like Random Forests, Gradient Boosting, and Voting Classifiers. It's user-friendly and integrates well with a variety of machine learning workflows, making it a suitable choice for our pipeline.
   - **XGBoost:** Known for its performance and scalability, XGBoost can be used for boosting tasks and offers robust tools for handling missing data and outliers, which could be beneficial for our prediction tasks.
   - **TensorFlow/Keras:** For deep learning-based ensembles, TensorFlow and Keras can be used to build custom ensemble models, allowing us to leverage neural network architectures in our predictions.

2. **Integration with Existing Tools:**
   - We can initially integrate ensemble models with outputs from ESM, AlphaFold-Multimer, and Rosetta by using them as feature inputs. This could involve using prediction scores from each tool as features in an ensemble model to improve the robustness of binding predictions.
   - An initial approach could involve using Scikit-learn's VotingClassifier to combine predictions from different models, allowing us to create a meta-model that captures diverse signals.

3. **Data and Training Considerations:**
   - We need a well-curated dataset for training, which should include cases of both successful and non-specific binding. This will help the ensemble model to learn effectively from diverse scenarios.
   - Cross-validation should be used extensively to ensure the model generalizes well across different data subsets, especially when predicting specificity.

4. **Potential Challenges:**
   - One challenge in ensemble learning is the potential complexity of model interpretation. Ensuring transparency in how predictions are made will be crucial, particularly when communicating results to non-technical stakeholders.

In summary, leveraging ensemble learning frameworks like Scikit-learn and XGBoost could significantly enhance our computational efforts by combining the strengths of different models. I look forward to the Computational Biologist's insights on the application of MD simulations in our pipeline.

## User

Computational Biologist, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Computational Biologist

In addressing the Principal Investigator's question on maximizing the impact of MD simulations, here are my thoughts:

1. **Selective Application of MD Simulations:**
   - **Prioritization Based on Initial Scores:** We should prioritize nanobodies that score highly in our initial computational assessments (ESM, AlphaFold-Multimer, Rosetta) and show promising experimental results in terms of specificity and binding affinity.
   - **Structural Novelty:** Focus on nanobodies that target unique or less-conserved regions of the RBD, as these are more likely to offer novel insights into binding mechanisms that static models might miss.

2. **Resource Optimization:**
   - **Focused Simulations:** Initially run shorter simulations (e.g., 10-20 ns) to quickly assess the stability and flexibility of top candidates. This allows us to screen a larger number of nanobodies with limited resources.
   - **Advanced Sampling Techniques:** Utilize techniques such as enhanced sampling methods (e.g., metadynamics or accelerated MD) to explore conformational space more efficiently, potentially gaining insights from shorter simulation times.

3. **Integration with Other Computational Tools:**
   - Use insights from MD simulations to refine static predictions, particularly in evaluating how conformational changes impact binding interface stability.
   - Incorporate dynamic metrics such as Root Mean Square Fluctuation (RMSF) and binding free energy calculations into the ensemble learning framework, enhancing the predictive power of our models.

4. **Balancing Computational Load:**
   - Consider cloud-based or distributed computing resources to manage the increased computational load associated with MD simulations. This allows flexibility in scaling up our simulation efforts as needed.

5. **Validation:**
   - Validate MD predictions with experimental data, ensuring that simulation results align with observed binding patterns and specificity. This feedback loop will be crucial in refining our predictive models.

By strategically applying MD simulations to key candidates, we can maximize their impact while managing computational resources effectively. I am eager to hear the Scientific Critic’s thoughts on validation techniques for non-specific binding predictions.

## User

Scientific Critic, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic

In addressing the Principal Investigator's query about validation techniques for non-specific binding predictions, here are some suggestions to ensure our models are both robust and reliable:

1. **Cross-Validation Methods:**
   - **K-Fold Cross-Validation:** This standard technique divides the dataset into k subsets and iteratively trains the model on k-1 subsets while testing on the remaining one. It helps ensure that our model generalizes well across different parts of the dataset.

2. **External Validation:**
   - **Independent Test Sets:** Use an independent dataset not involved in model training to assess the model's performance. This is critical for evaluating how well our predictions perform on completely unseen data.
   - **Challenge Datasets:** Employ datasets specifically designed to challenge models with difficult cases, such as borderline or ambiguous binding interactions, to test robustness.

3. **Performance Metrics:**
   - **Precision-Recall Curves:** Since we anticipate class imbalance (more specific than non-specific interactions), precision-recall curves can provide a more informative measure of model performance than ROC curves.
   - **F1 Score:** This metric balances precision and recall, offering an overall sense of the model's accuracy in predicting non-specific binding.

4. **Interpretability:**
   - **Feature Importance Analysis:** Determine which features most influence predictions, aiding in the understanding of model decisions and ensuring they align with biological expectations.
   - **Shapley Values or LIME:** These methods can provide insights into model predictions, helping to explain why a particular binding prediction was made.

5. **Iterative Feedback:**
   - Use experimental results to iteratively refine models. If a nanobody predicted to avoid non-specific binding shows unexpected behavior experimentally, retrain the model using this new data to enhance predictive accuracy.

By employing these validation techniques, we can ensure that our predictions regarding non-specific binding are robust and reliable, ultimately contributing to the success of our nanobody design efforts. I look forward to the Principal Investigator's synthesis of our discussions and the final decisions to guide our project's progression.

## User

Principal Investigator, please summarize the meeting in detail for future discussions, provide a specific recommendation regarding the agenda, and answer the agenda questions (if any) based on the discussion while strictly adhering to the agenda rules (if any).

As a reminder, here is the agenda for the meeting:

You are working on a research project to use machine learning to develop antibodies or nanobodies for the newest variant of the SARS-CoV-2 spike protein that also, ideally, have activity against other circulating minor variants and past variants. Your team previous decided to modify existing nanobodies to improve their binding to the newest variant of the SARS-CoV-2 spike protein. Your team has designed 92 mutated nanobodies (23 each for the wild-type nanobodies H11-D4, Nb21, Ty1, and VHH-72) to improve their binding to the KP.3 variant of the SARS-CoV-2 spike protein receptor binding domain (RBD). Each nanobody has 1-4 mutations relative to the wild-type nanobody. Your team used ESM log-likelihood ratios (ESM LLR) to score the nanobody mutations independent of the antigen, AlphaFold-Multimer to predict the structure of the mutated nanobody in complex with the KP.3 RBD and compute the interface pLDDT (AF ipLDDT) as a metric of binding confidence, and Rosetta to calculate the binding energy of the mutated nanobody in complex with the KP.3 RBD (RS dG) based on the AlphaFold-Multimer predicted structure followed by a Rosetta relaxation. You have ranked the mutant nanobodies and selected the top ones using a weighted score of WS = 0.2 * (ESM LLR) + 0.5 * (AF ipLDDT) - 0. 3 * (RS dG). The 92 selected nanobodies were tested along with the four wild-type nanobodies using an ELISA assay to measure binding to the Wuhan, JN.1, KP.3, KP2.3, and BA.2 strains of the SARS-CoV-2 spike RBD. Note that the JN.1 strain is closely related to KP.3 and KP2.3. BSA was used as a negative control. Most of the mutated nanobodies showed at least moderate expression levels. The ELISA results are as follows:

H11-D4: The wild-type only binds to the Wuhan RBD. Most mutants show binding to the Wuhan RBD as well, including one with a higher binding level than the wild-type. However, that mutant and two others bind non-specifically to the negative control BSA along with other strains of the SARS-CoV-2 RBD. No mutant nanobody shows specific binding to any strain other than the Wuhan RBD.

Nb21: The wild-type only binds to the Wuhan RBD. All mutant nanobodies also bind to the Wuhan RBD. There are no non-specific binders. One mutant nanobody with mutations I77V, L59E, Q87A, and R37Q binds to the Wuhan RBD (strong binding), the JN.1 RBD (moderate binding), and the KP.3 RBD (weak binding). Thus, this mutant introduces specific binding to JN.1 and KP.3 that the wild-type does not possess, and it increases binding to the Wuhan RBD.

Ty1: The wild-type only binds to the Wuhan RBD. Many mutant nanobodies do not show binding, but several show moderate binding to the Wuhan RBD. One mutant nanobody with mutations V32F, G59D, N45S, and F32S binds to the Wuhan RBD (strong binding) and the JN.1 RBD (moderate binding). This mutant introduces specific binding to JN.1 that the wild-type does not possess, and it increases binding to the Wuhan RBD. Additionally, there are is one mutant with weak, non-specific binding to BSA and other RBD strains.

VHH-72: The wild-type only binds to the Wuhan RBD. Most mutants show binding to the Wuhan RBD as well, including several with a higher binding level than the wild-type. Two mutant nanobodies bind non-specifically to BSA and several RBD strains. No mutant nanobody shows specific binding to any strain other than the Wuhan RBD.

Based on these results, you must decide how to proceed to design further improved nanobodies for recent variants of SARS-CoV-2. You may either continue to pursue identifying binders to the KP.3 RBD or you may decide to target a different strain or strains of the SARS-CoV-2 spike RBD. Your team should select another 92 mutant nanobodies to test experimentally. This time, you do not have to test an equal number of mutants for each wild-type nanobody, and you may even entirely leave out some wild-type nanobodies. You can either start again from the wild-type nanobodies and introduce mutations or begin with one of the previously designed nanobodies. You may use ESM, AlphaFold-Multimer, and/or Rosetta in similar ways to your previous design process, or you can change the design workflow and/or the computational tools that are used. You may introduce as many mutations as you see fit. You should aim to design nanobodies that bind specifically to the RBD of recent variants of SARS-CoV-2 and do not bind non-specifically to BSA. You should provide a rationale for all of your decisions.


As a reminder, here are the agenda questions that must be answered:

1. Will you continue to target the KP.3 RBD or will you target a different strain or strains of the SARS-CoV-2 spike RBD?

2. Which wild-type nanobody or nanobodies will you select for further improvement?

3. How many mutant nanobodies will you design for each of those wild-type nanobodies (92 total)?

4. Will you begin with the wild-type nanobody itself and introduce mutations, or will you begin with one of the previously designed mutant nanobodies?

5. If you are beginning with previously designed mutant nanobodies, which one or ones will you start with?

6. Will you use ESM, AlphaFold-Multimer, and/or Rosetta in similar ways to your previous design process, or will you change the design workflow and/or the computational tools that are used?

7. What computational pipeline will you use to design the 92 mutant nanobodies?

8. How many mutations will you introduce in each nanobody?

9. How will you avoid non-specific binding to BSA?

Your summary should take the following form.

### Agenda

Restate the agenda in your own words.

### Team Member Input

Summarize all of the important points raised by each team member. This is to ensure that key details are preserved for future meetings.

### Recommendation

Provide your expert recommendation regarding the agenda. You should consider the input from each team member, but you must also use your expertise to make a final decision and choose one option among several that may have been discussed. This decision can conflict with the input of some team members as long as it is well justified. It is essential that you provide a clear, specific, and actionable recommendation. Please justify your recommendation as well.

### Answers

For each agenda question, please provide the following:

Answer: A specific answer to the question based on your recommendation above.

Justification: A brief explanation of why you provided that answer.

### Next Steps

Outline the next steps that the team should take based on the discussion.

## Principal Investigator

### Agenda

We are tasked with refining our strategy for designing nanobodies that specifically bind to recent variants of the SARS-CoV-2 spike protein, while avoiding non-specific binding. Our previous efforts targeted the KP.3 RBD using a computational pipeline involving ESM, AlphaFold-Multimer, and Rosetta. We must now decide if we will continue focusing on the KP.3 variant or target additional variants, determine which wild-type nanobodies or previously designed mutants to further develop, and decide on the computational and experimental approaches for designing 92 new mutant nanobodies.

### Team Member Input

- **Immunologist:** Emphasized the importance of broadening our target to include multiple variants, such as JN.1 and KP2.3, to increase cross-reactivity potential while minimizing unintended cross-reactivity with other coronaviruses. Suggested using structural homology and experimental controls.

- **Machine Learning Specialist:** Supported incorporating ensemble learning to strengthen our prediction accuracy by combining outputs from various models. Highlighted the need for data integration and model validation to avoid non-specific binding predictions.

- **Computational Biologist:** Advocated for the use of MD simulations to gain dynamic insights into binding interactions, suggesting prioritization of promising candidates for these resource-intensive analyses. Stressed the importance of balancing computational load and integrating dynamic metrics into our workflow.

- **Scientific Critic:** Suggested employing robust validation techniques, including cross-validation and feature importance analysis, to ensure the reliability of our models, particularly for non-specific binding predictions. Highlighted the importance of using diverse and challenging datasets for model training.

### Recommendation

Given the team's input, I recommend broadening our target to include JN.1 and KP2.3 variants alongside KP.3. We should focus on further improving the Nb21 and Ty1 nanobodies due to their demonstrated potential for cross-variant binding. Our computational strategy should integrate ensemble learning, enhancing our prediction accuracy by combining model outputs. Additionally, we should apply MD simulations selectively to high-priority candidates to gain deeper insights into binding dynamics. This approach balances the need for specificity and cross-reactivity with computational feasibility, optimizing our chances for successful nanobody design.

### Answers

1. **Will you continue to target the KP.3 RBD or will you target a different strain or strains of the SARS-CoV-2 spike RBD?**
   - **Answer:** Target KP.3, JN.1, and KP2.3 RBDs.
   - **Justification:** Broadening our target to include related variants increases the likelihood of developing cross-reactive and broadly effective nanobodies.

2. **Which wild-type nanobody or nanobodies will you select for further improvement?**
   - **Answer:** Nb21 and Ty1.
   - **Justification:** These nanobodies showed cross-variant binding potential, making them strong candidates for further development.

3. **How many mutant nanobodies will you design for each of those wild-type nanobodies (92 total)?**
   - **Answer:** Design 46 mutants for each nanobody.
   - **Justification:** Allocating equal resources to each promising candidate ensures a balanced exploration of potential improvements.

4. **Will you begin with the wild-type nanobody itself and introduce mutations, or will you begin with one of the previously designed mutant nanobodies?**
   - **Answer:** Begin with previously designed mutants.
   - **Justification:** These mutants have already demonstrated enhanced binding properties and serve as a solid foundation for further optimization.

5. **If you are beginning with previously designed mutant nanobodies, which one or ones will you start with?**
   - **Answer:** Use the Nb21 mutant with I77V, L59E, Q87A, R37Q and the Ty1 mutant with V32F, G59D, N45S, F32S.
   - **Justification:** These mutants exhibited specific cross-variant binding, providing a promising basis for further development.

6. **Will you use ESM, AlphaFold-Multimer, and/or Rosetta in similar ways to your previous design process, or will you change the design workflow and/or the computational tools that are used?**
   - **Answer:** Use similar tools with an integrated ensemble learning approach.
   - **Justification:** Maintaining our current pipeline but enhancing it with ensemble learning improves prediction accuracy and model robustness.

7. **What computational pipeline will you use to design the 92 mutant nanobodies?**
   - **Answer:** ESM, AlphaFold-Multimer, Rosetta, integrated with ensemble learning models.
   - **Justification:** This pipeline leverages the strengths of different models to optimize design predictions.

8. **How many mutations will you introduce in each nanobody?**
   - **Answer:** 2-4 mutations per nanobody.
   - **Justification:** This mutation range balances the exploration of sequence space with structural stability.

9. **How will you avoid non-specific binding to BSA?**
   - **Answer:** Use ML models trained on specific and non-specific binding data, incorporate physicochemical property analysis, and perform rigorous validation.
   - **Justification:** These strategies provide a data-driven approach to minimizing non-specific interactions.

### Next Steps

1. **Begin computational design:** Implement the computational strategies and begin designing the 92 mutant nanobodies.
2. **Conduct structural homology analysis:** Evaluate potential cross-reactivity with non-target coronaviruses using in silico tools.
3. **Prepare experimental validation plan:** Develop assays and controls for testing specificity and binding affinity.
4. **Integrate ensemble learning:** Set up ensemble models and train them on existing datasets to enhance prediction accuracy.
5. **Select top candidates for MD simulations:** Identify high-priority nanobodies for detailed dynamic analysis to refine structural predictions.

These steps will guide our project progression, ensuring efficient and targeted development of effective nanobodies.

